See how you can increase the quality of COPD care and reduce costs
Find your path to value-based healthcare with GSK
On this page, you’ll find useful information that will help you to understand and implement strategies that result in the delivery of value-based healthcare programmes. In addition, you’ll be able to access resources and obtain the support you need to achieve your goals1.
There is scope for ICBs to implement value-based healthcare programmes where appropriate, which can help to reduce the disease burden of COPD.
Value-based healthcare is the equitable, sustainable and transparent use of the available resources to achieve better outcomes and experiences for every person1.
Implementing a successful value-based care program should result in1,2:
Care quality
improvement
Reduced
costs
Waste
reduction
Improved health
outcomes
Reduced health
inequalities
Find your value-based healthcare opportunity and get started today!
For a summary on COPD as a focus for value-based healthcare, download our free "Redefining Healthcare in COPD" leave piece.
COPD represents a significant financial burden within all regions of the UK and costs the NHS £4.5 billion in 20233.
Issues with unequal care mean that 22.4% of people with COPD wait ≥5 years for a diagnosis. Individuals experiencing material deprivation are more likely to be affected by COPD (based on a survey of 6,551 respondents with COPD)4,5,6.
ICBs can implement value-based healthcare in relation to COPD as the figures below highlight the economic burden of this disease3,4.
Total annual economic cost of COPD in the UK3,4
This table shows the results of the asthma and lung UK 2022 survey in which 4983 COPD patients participated.
| Costs (GBP, million)* | |||||||
|---|---|---|---|---|---|---|---|
| Country | Treatment | Maintenance | Exacerbation | Adverse effects | Productivity | QALY | Total |
| England | 651 | 946 | 1,388 | 913 | 1,743 | 2,261 | 7,902 |
| Wales | 35 | 51 | 75 | 49 | 94 | 112 | 427 |
| Scotland | 40 | 57 | 84 | 56 | 106 | 137 | 480 |
| Northern Ireland | 18 | 27 | 39 | 26 | 49 | 64 | 222 |
| Total | 744 | 1,081 | 1,587 | 1,044 | 1,992 | 2,584 | 9,032 |
Proportion of COPD patients surveyed who know what their medicines are for and how to use them, organised by level of material deprivation
4983 responded to the question on knowledge of COPD medicines by deprivation level.
If you’d like to learn more about COPD value-based healthcare, book a free expert session
You can also read...
Case studies
Read about real initiatives that have already been implemented.
Resources
Utilise our useful dashboards and tools.
Education
Explore our educational offering designed to help healthcare professionals support COPD patients.
UK ICBs have already implemented impactful strategies to support their quality, equity, and efficiency goals.
The following implementation strategy models and case studies highlight best-practice for value-based care programmes resulting in real-world impact for patients and ICBs.
Click on the drop-down menu titles to find out more about examples regarding the potential benefits of achieving targets in COPD.
The following case studies are for illustrative purposes only and are not GSK owned.
1. Using digital innovations to support the self-management of COPD patients7,8
Location
Bristol, North Somerset and South Gloucestershire ICB identified the need to actively deploy digital innovations to support the growing burden of disease and associated costs.
Actions
- COPD digital CHAMP (Coaching Health App Implementation Partnership) project – digital remote monitoring technology developed to improve patient safety and reduce emergency admissions
- Developed an implementation strategy for the myCOPD self-management application by using Digital Health Champions
- Patients referred to the app from acute, primary, secondary and community care colleagues
Outcomes
- Projected Benefit to Cost Ratio of 1.2 after 5 years (for every £1 spent, the model would return £1.20)
- Largest benefit (62% of the total benefit generated) being reduction in admissions – generating £402,000 over 5 years. Followed by the reduction in bed days per admission (37% of the total benefit generated) – generating £237,000 after 5 years. Finally reduction in inhaler wastage (1% of the total benefit generated) – generating £7,000 after 5 years (money savings generated are a non-cash-releasing benefit)
- Initial losses were seen in the first year due to higher implementation costs, which reduced to £89,484 from the second year onwards.
- Some patients felt supported and were able to engage with the digital technology. However, there were those who chose not to engage with the myCOPD application, despite the support from Digital Health Champions.
COPD, chronic obstructive pulmonary disease; ICB, integrated care board.
Book a free expert session to discuss GSK specific case studies
You can also read...
Intro
Find out more about a value-based healthcare approach to COPD treatment.
Resources
Utilise our useful dashboards and tools.
Education
Explore our educational offering designed to help healthcare professionals support COPD patients.
GSK is committed to ICB collaborations that result in value for COPD patients and the NHS
We can provide immediate support through the following useful resources and tools.
GSK do not own all of the resources listed below.
Dashboards
The following are examples of dashboards that ICBs can access to obtain and analyse data on both outcomes and resources:
Local overview and trust dashboards
The local overview and trust dashboards can provide ICBs with data on patient admissions, average costs and average length of stay at the local or trust level.
Simplified practice prescribing data (PPD) dashboard
ICBs can obtain prescribing data when using the simplified practice prescribing data (PPD) dashboard.
Health inequalities dashboard
The health inequalities dashboard enables ICBs to access regional data on mortality, average number of comorbidities, return to care within 30 days. This dashboard also provides ICBs with data on admissions due to smoking, alcohol abuse and obesity.
Scotland/Wales: Hospital Activity dashboard
Scotland and Wales specific hospital activity data can also be obtained by ICBs when using the respective hospital activity dashboards.
Tools to support the identification, prioritisation and review of COPD patients
Searches for your clinical system
GSK have co-developed Emis, SystmOne, and Vision searches to identify patient cohorts from the COPD register:
- Cohort One: MITT patients
- Cohort Two: ICS/LABA therapy only
- Cohort Three: LAMA/LABA therapy only
- Cohort Four: LAMA monotherapy
Please Note: There is no direction or bias towards using any GSK products.
HCP, healthcare professional; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MITT, Multiple Inhaler Triple Therapy.
Project implementation guide
A guide document to provide PCNs/clusters with what could be included in a COPD therapy review project.
COPD, chronic obstructive pulmonary disease; PCN, primary care network.
To request dashboard resources and get support with implementation, get in touch with us today
You can also read...
Intro
Find out more about a value-based healthcare approach to COPD treatment.
Case studies
Read about real initiatives that have already been implemented.
Education
Explore our educational offering designed to help healthcare professionals support COPD patients.
Education and Training
CPD-accredited, COPD educational modules
GSK have funded and developed CPD-accredited COPD educational modules, that have been designed to provide healthcare professionals with the confidence and knowledge they need to effectively support COPD patients. This educational resource is made up of the following modules:
COPD 101
How do to a COPD review
COPD management
COPD inhalers
Discussing the environmental impact of COPD
inhalers with patients
COPD, chronic obstructive pulmonary disease; CPD, continuing professional development.
Device demonstration & inhaler training (Whistle)
GSK can assist in giving healthcare professionals the tools they need so that they can successfully educate patients and raise the quality of care.
The training whistle is for healthcare professionals to show patients how to use a device correctly and help them understand the correct inspiratory flow needed.
To request access to educational modules or training resources, get in touch today
You can also read...
Intro
Find out more about a value-based healthcare approach to COPD treatment.
Case studies
Read about real initiatives that have already been implemented.
Resources
Utilise our useful dashboards and tools.
For more information, including: advice, resources or tools on implementing value-based healthcare, please get in touch with a GSK representative.
Start realising value now
To book a free expert session, please register below:
To subscribe to our latest information, please complete the form:
References
- Centre for Evidence-Based Medicine Report. Defining Value-based Healthcare in the NHS. 2019. Available at: https://www.cebm.net/wp-content/uploads/2019/04/Defining-Value-based-healthcare-in-the-NHS_201904.pdf. Accessed September 2024
- Commonwealth fund. Value-Based Care: What it is, and Why it’s Needed.2023. Available at: https://www.commonwealthfund.org/publications/expaliner/2023/feb/value-based-care-what-it-is-why-its-needed. Accessed September 2024
- Asthma + Lung UK. Investing in breath: Measuring the economic cost of asthma and COPD in the UK and identifying ways to reduce it through better diagnosis and care. 2023. Available at: https://www.asthmaandlung.org.uk/investing-breath-measuring-economic-cost-asthma-copd-uk-identifying-ways-reduce-it-through-better. Accessed September 2024
- Asthma + Lung UK. Delayed diagnosis and unequal care. 2022. Available at: https://www.asthmaandlung.org.uk/sites/default/files/2023-03/delayed-diagnosis-unequal-care.pdf. Accessed September 2024
- British Lung foundation. The battle for breath - the impact of lung disease in the UK. Available at: battle-breath-report (asthmaandlung.org.uk). Accessed September 2024
- Asthma + Lung UK. The invisible threat: How we can protect people from air pollution and create a fairer, healthier society. 2021. Available at: The invisible threat: how we can protect people from air pollution and create a fairer, healthier society (asthmaandlung.org.uk). Accessed September 2024
- NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board. COPD Digital CHAMP (Coaching Health App Implementation Partnership). Available at: https://bnssg.icb.nhs.uk/get-involved/copd-digital-champ-coaching-health-app-implementation-partnership/. Accessed September 2024
- West of England Academic Health Science Network. Summary of the COPD Digital CHAMP Evaluation. 2023. Available at: https://www.weahsn.net/wp-content/uploads/2023/05/Summary-of-the-COPD-Digital-CHAMP-Evaluation.pdf. Accessed September 2024
PM-GB-CPU-WCNT-240001 | September 2024